Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities

Author:

Playdon Mary C12,Hardikar Sheetal23,Karra Prasoona12,Hoobler Rachel12,Ibele Anna R4,Cook Katherine L567ORCID,Kumar Amanika8,Ippolito Joseph E9ORCID,Brown Justin C101112ORCID

Affiliation:

1. Department of Nutrition and Integrative Physiology, College of Health, University of Utah , Salt Lake City, UT, USA

2. Cancer Control and Population Sciences Program, Huntsman Cancer Institute , Salt Lake City, UT, USA

3. Department of Population Health Sciences, School of Medicine, University of Utah , Salt Lake City, UT, USA

4. Department of Surgery, School of Medicine, University of Utah , Salt Lake City, UT, USA

5. Department of Surgery, Wake Forest School of Medicine , Winston-Salem, NC, USA

6. Department of Cancer Biology, Wake Forest School of Medicine , Winston-Salem, NC, USA

7. Comprehensive Cancer Center, Wake Forest School of Medicine , Winston-Salem, NC, USA

8. Division of Gynecologic Surgery, Mayo Clinic , Rochester, MN, USA

9. Mallinckrodt Institute of Radiology, Washington University School of Medicine , St. Louis, MO, USA

10. Pennington Biomedical Research Center , Baton Rouge, LA, USA

11. Louisiana State University Health Sciences Center New Orleans School of Medicine , New Orleans, LA, USA

12. Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center , New Orleans, LA, USA

Abstract

Abstract Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.

Funder

National Cancer Institute

National Institutes of Health

National Institute of General Medicine Sciences

National Institute of Diabetes and Digestive and Kidney Diseases

American Institute for Cancer Research

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3